BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221101
DTEND;VALUE=DATE:20221104
DTSTAMP:20260516T035239
CREATED:20220727T092002Z
LAST-MODIFIED:20220728T084955Z
UID:34790-1667260800-1667519999@www.pharmajournalist.com
SUMMARY:6th Dermatology Drug Development Summit
DESCRIPTION:The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. \nEnsure you join this year’s 150+ expert community in-person to: \n\nUncover recent studies evaluating critical inflammatory and auto-immune pathways\nGain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, versus IL-17 associated diseases\nAssess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.\nObtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa\, Vitiligo\, Rare Disease\, and Alopecia Areata\n\nView the event program here: https://ter.li/g3z67z \nRegister here: https://ter.li/vu3tx9 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/6th-dermatology-drug-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221107
DTEND;VALUE=DATE:20221110
DTSTAMP:20260516T035239
CREATED:20220825T102329Z
LAST-MODIFIED:20220825T102329Z
UID:35008-1667779200-1668038399@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement – Human Nutrition Summit
DESCRIPTION:Returning to Boston for 2022\, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations\, practical applications and clinical benefits of microbiome targeting food\, beverages and supplements to pave the route to commercial success in the consumer health setting. \nGet up to speed on this dynamic industry with expertise shared from the likes of Bayer\, Postbiotics Plus\, Amazentis and many others\, as the titans of industry unite to: \n\nShowcase the latest scientific findings on the mechanism and functional role of novel microbiome targeting ingredients\nShine a spotlight on the future of postbiotics\, and advance commercialization of microbiome-targeted nutritional interventions\nAdvance commercialization of microbiome-targeted nutritional interventions\n\nWith consumers demanding to have greater control over personal health and wellbeing\, join your community of 100+ industry experts from global CPG companies\, innovative start-ups and biotechs to usher in a new wave of personalised nutrition. \nTo know more visit: https://bit.ly/3clIDZQ
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-human-nutrition-summit/
LOCATION:TBC
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221109
DTEND;VALUE=DATE:20221112
DTSTAMP:20260516T035239
CREATED:20220728T083732Z
LAST-MODIFIED:20220728T083732Z
UID:34796-1667952000-1668211199@www.pharmajournalist.com
SUMMARY:6th Antifibrotic Drug Development Summit (AFDD)
DESCRIPTION:Returning for the 6th year\, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF\, NASH\, CKD and more in one place at one time\, so you can advance the progress of your antifibrotic therapies. \nFrom exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ\, cross-disease\, cross-discipline discussion forum is here to transform your fibrosis research. \nJoin 100+ industry super giants from Boehringer Ingelheim\, Genentech\, Gilead\, Pfizer\, Novartis\, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development. \nTo know more visit: https://ter.li/u60ni5
URL:https://www.pharmajournalist.com/event/6th-antifibrotic-drug-development-summit-afdd/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221116
DTSTAMP:20260516T035239
CREATED:20220609T062845Z
LAST-MODIFIED:20220609T062845Z
UID:34376-1668384000-1668556799@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD 2022
DESCRIPTION:SAE Media Group’s Inaugural Conference… \nMedical Devices and IVD 2022\n14 – 15 November 2022\nLondon\, UK\nwww.medicaldevices-ivd.com/PJ \nNavigating The MDR and IVDR and Best Strategies for Compliance  \nSAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference\, taking place on 14 – 15 November 2022 in London\, UK. \n \nThe MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. \nThe conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition\, the conference will consider the evolving regulatory landscape for digital health software. \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this\n\nWHO SHOULD ATTEND: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nDevice Manufacturing\nRegulatory Affairs\nIVDR\nMDR\nCMC\nCompliance\nRisk Management\nTraceability\nVigilance\nProduct Development\nPFS\nCombination Products\n\nTo find out more\, please visit: www.medicaldevices-ivd.com/PJ \nEARLY BIRD RATES: \n\nBOOK BY 30TH JUNE TO SAVE £200\nBOOK BY 30TH SEPTEMBER TO SAVE £100\n\nADDITIONAL CONTACT INFORMATION: \n\nE: ngaloria@smi-online.co.uk\nT: +44 (0) 20 7827 6164\n\nFOLLOW US ON: \n\nTwitter: @SAEMGPharma\n\nLinkedIn: SAE Media Group Pharma
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-2022/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T035239
CREATED:20220805T095510Z
LAST-MODIFIED:20220805T095849Z
UID:34850-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: USA 2022
DESCRIPTION:The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes\, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges\, drug developers will have the opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. Furthermore\, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts\, including the Head of CBER\, on topics including how to handle USP 61/62\, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs\, pharma voices\, investment bodies\, and more on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: www.microbiomeconnectusa.com
URL:https://www.pharmajournalist.com/event/microbiome-connect-usa-2022/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T035239
CREATED:20221024T222603Z
LAST-MODIFIED:20221024T222746Z
UID:35596-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Liquid Biopsy Surveillance & Early Detection Summit
DESCRIPTION:Recognize Disease Hallmarks Earlier for Improved Patient Outcomes \nGain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring\, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access \nIn the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca\, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it\, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development. \nWith technology maturity on the near horizon\, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes. \nAs drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting\, here lies your best opportunity to harness game-changing technologies to define leading stratification\, surrogate endpoint\, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic. \nProviding a path forward for early detection & surveillance to become a widespread patient reality\, unite with 80+ Translational\, Biomarker\, Clinical\, Regulatory\, Precision Medicine\, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention. \nTo know more visit: https://ter.li/0kjtfi
URL:https://www.pharmajournalist.com/event/liquid-biopsy-surveillance-early-detection-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T035239
CREATED:20220720T112134Z
LAST-MODIFIED:20220720T112134Z
UID:34732-1669593600-1669939199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Summit 2022
DESCRIPTION:The past twelve months have culminated in an unprecedented level of excitement\, investment\, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy\, in the context of increased regulatory scrutiny and safety challenges\, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. \nThis year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech\, pharma and academia to continue to develop resilient\, long-lasting and robust analytical tools to enhance the safety\, quality and efficacy of gene therapy products.   \nWhether you are focusing on specific characterization methods\, enhancing your genome sequencing\, advancing your understanding of full and partial particles\, or advancing your early-stage bioassays\, with 4 tracks\, 8 pre-conference workshops and a post-conference focus day\, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development\, giving you the chance to address and overcome challenges. \nIf you work in quality control\, quality assurance\, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments\, bridging between analytical methods with regards to QC/PD\, and enhancing in-process development support. \nWhether you’re working with AAV\, non-viral vectors or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/w2diiu
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-summit-2022/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221201
DTSTAMP:20260516T035239
CREATED:20220819T112405Z
LAST-MODIFIED:20220819T112405Z
UID:34933-1669593600-1669852799@www.pharmajournalist.com
SUMMARY:2nd Rare CNS & Neurodevelopmental Drug Development Summit
DESCRIPTION:Developing New Outcome Measures\, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare\, Genetic CNS Disorders \nWith more clinical data emerging\, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results\, outcomes\, and functional biomarkers\, catapulting this critical field forwards. \nJoin 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma\, biotech\, academia\, and patient advocacy groups\, paving the way towards symptomatic and successful disease modifying treatments. \nTightly focused on industry progress\, stakeholders will explore ASOs\, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference. \nDon’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design\, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers\, emerging therapeutic targets and translational biology. \nIf you are working towards treatments for rare CNS and neurodevelopmental disorders\, including (but not limited to) Angelman Syndrome\, Rett syndrome\, Fragile X\, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics\, this is the platform you need. \nTo know more visit: https://ter.li/9yzux5
URL:https://www.pharmajournalist.com/event/2nd-rare-cns-neurodevelopmental-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T035239
CREATED:20220811T093237Z
LAST-MODIFIED:20220811T093237Z
UID:34895-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:4th Inflammasome Therapeutics Summit
DESCRIPTION:The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma\, biotechs\, and academic KOLs\, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs\, which are shaking up the immunology R&D landscape. \nAs the space eagerly awaits data readouts from proof-of-concept trials\, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on: \n\nDeciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system \nOvercoming limitations of preclinical models\, identifying clinically meaningful biomarkers of inflammasome inhibition\, and defining good clinical endpoints \nTaming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets \nDelving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful\n\nJoin 120+ fellow peers and industry heavyweights this Fall including NodThera\, Novartis\, Zyversa Therapeutics\, and more\, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/4th-inflammasome-therapeutics-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T035239
CREATED:20220811T093818Z
LAST-MODIFIED:20220815T091224Z
UID:34899-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:6th Obesity & NASH Drug Development Summit
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints\, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. \n \nWith mounting competition for the market in obesity and all eyes on the next wave of NASH candidates\, the 6th Obesity & NASH Drug Development Summit\, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. \nJoin 150+ industry pioneers in Boston including pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\, Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pipeline towards approved treatment. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/6th-obesity-nash-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T035239
CREATED:20220824T095329Z
LAST-MODIFIED:20220824T114844Z
UID:34996-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:3rd CRISPR 2.0 Summit
DESCRIPTION:Recognized with a Nobel Prize in 2020\, CRISPR has opened the floodgates for a new era of gene editing therapies\, promising to transform genetic disease treatments. With a well-established early field of genomics research\, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit\, including Cas nucleases\, base and prime editing technologies\, and innovative delivery platforms. \nThe 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic. \nAcross three days of content\, co-designed with 27+ industry thought leaders\, this streamlined one-track summit will unite 100+ key players in the CRISPR space\, from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to market for your CRISPR gene editing program. \nHere’s a snapshot of our 27+ thought leaders: \n\nKiran Musunuru\, Professor of Medicine\, Perelman School of Medicine\, University of Pennsylvania\nAmy Simon\, Chief Medical Officer\, Beam Therapeutics\nJane Grogan\, Chief Scientific Officer\, Graphite Bio\nLiron Walsh\, Head of Development; In Vivo Programs\, Intellia Therapeutics\nJeremy Duffield\, Chief Scientific Officer\, Prime Medicine\nEric B. Kmiec\, Executive Director & Chief Scientific Officer\, Christiana Care Gene Editing Institute\nRafi Emmanuel\, Senior Vice President – Research & Development\, Emendo Biotherapeutics\nJohn Murphy\, Chief Scientific Officer\, Arbor Biotechnologies\nInge Yung-Chih Cheng\, Principal Scientist\, Pfizer\nJoey Riepsaame\, Head of Genome Engineering\, University of Oxford\nRammohan Devulapally\, Principal Scientist\, GenEdit\n\nBe part of the community as we dive deep into: \n\nRefining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy\, with help from GenEdit and the latest research from the David Liu Lab.\nFrom bench to bedside: translating basic CRISPR research into a viable therapeutic product\, with Beam Therapeutics\nLeverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders\, with Prime Medicine and UC Irvine.\n\nAnd more! \nJoin this unmissable summit and network experts from the likes of Beam Therapeutics\, The David Liu Lab\, Pfizer\, GenEdit\, AZ\, GSK\, Caribou Biosciences\, Prime Medicine\, Intellia Therapeutics and many more. \nTo know more visit: https://ter.li/vumobp
URL:https://www.pharmajournalist.com/event/3rd-crispr-2-0-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR